2026

• Christopher Elnan Kvistad; Torbjørn Kråkenes; Trygve Holmøy et al. (2026). Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS). (ekstern lenke)
• Marie Ytterdal; Casper Eugen Sandvik; Trygve Holmøy et al. (2026). The neural transdifferentiation potential of bone marrow mesenchymal stem cells. (ekstern lenke)

2022

• Christopher Elnan Kvistad; Torbjørn Kråkenes; Gudveig Cecilie Gjerde Gjengedal et al. (2022). Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke – A Systematic Review and Meta-Analysis. (ekstern lenke)
• Margrethe Raspotnig; Torbjørn Kråkenes; Ida Ajvazi Herdlevær et al. (2022). Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue. (ekstern lenke)

2021

• Xiao Liang; Atefeh Kianian; Anbin Chen et al. (2021). Stem cell derived astrocytes with POLG mutations and mitochondrial dysfunction including abnormal NAD+ metabolism is toxic for neurons. (ekstern lenke)

2023

• Torbjørn Kråkenes; Stig Wergeland; Niyaz Abdulbaqi Abdulmajid Al-Sharabi et al. (2023). The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination. (ekstern lenke)
• Ida Margrethe Uggerud; Torbjørn Kråkenes; Hirokazu Hirai et al. (2023). Development and Optimization of a Multilayer Rat Purkinje Neuron Culture. (ekstern lenke)

2024

• Torbjørn Kråkenes; Casper Eugen Sandvik; Marie Ytterdal et al. (2024). The Therapeutic Potential of Exosomes from Mesenchymal Stem Cells in Multiple Sclerosis. (ekstern lenke)
• Sonia Gavasso; Torbjørn Kråkenes; Håkon Olsen et al. (2024). The Therapeutic Mechanisms of Mesenchymal Stem Cells in MS—A Review Focusing on Neuroprotective Properties. (ekstern lenke)
• Xiao Liang; Anbin Chen; Atefeh Kianian et al. (2024). Activation of Neurotoxic Astrocytes Due to Mitochondrial Dysfunction Triggered by POLG Mutation. (ekstern lenke)
• Eirik Tveit Solheim; Yola Gerking; Torbjørn Kråkenes et al. (2024). Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell proliferation following knockout of CDR2L. (ekstern lenke)
• Christopher Elnan Kvistad; Torbjørn Kråkenes; Sonia Gavasso et al. (2024). Neural regeneration in the human central nervous system—from understanding the underlying mechanisms to developing treatments. Where do we stand today?. (ekstern lenke)

2020

• Ida Ajvazi Herdlevær; Torbjørn Kråkenes; Manja Schubert et al. (2020). Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration. (ekstern lenke)
• Torbjørn Kråkenes; Ida Ajvazi Herdlevær; Margrethe Raspotnig et al. (2020). Reply to “CDR2 and CDR2L Yo Antigens in Paraneoplastic Cerebellar Degeneration”. (ekstern lenke)

2018

• Cecilie Totland; Torbjørn Kråkenes; Kibret Yimer Mazengia et al. (2018). Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer. (ekstern lenke)

2019

• Torbjørn Kråkenes; Ida Ajvazi Herdlevær; Margrethe Raspotnig et al. (2019). CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration. (ekstern lenke)
• Kristin Nielsen Varhaug; Torbjørn Kråkenes; Maria Nordheim Alme et al. (2019). Mitochondrial complex IV is lost in neurons in the cuprizone mouse model. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.